Change in spinal bone mineral density as estimated by Hounsfield units following osteoporosis treatment with romosozumab, teriparatide, denosumab, and alendronate: an analysis of 318 patients.
Anthony L MikulaNikita LakomkinAbdelrahman M HamoudaMegan C EversonZach PenningtonRahul KumarZachariah W PinterMichael L MartiniMohamad BydonKurt A KennelFrancis BaffourAhmad NassrBrett FreedmanArjun S SebastianKingsley Abode-IyamahPaul A AndersonJeremy L FogelsonBenjamin D ElderPublished in: Journal of neurosurgery. Spine (2024)
Patients treated with romosozumab for a mean of 10.5 months and teriparatide for a mean of 23 months experienced improved spinal bone mineral density as estimated by CT-based opportunistic HU. Given the shorter duration of effective treatment, romosozumab may be the preferred medication for optimization of osteoporotic patients in preparation for elective spine fusion surgery.
Keyphrases
- bone mineral density
- postmenopausal women
- body composition
- end stage renal disease
- spinal cord
- minimally invasive
- newly diagnosed
- healthcare
- ejection fraction
- magnetic resonance imaging
- chronic kidney disease
- magnetic resonance
- peritoneal dialysis
- combination therapy
- coronary artery disease
- prognostic factors
- high resolution
- patients undergoing
- patient reported outcomes
- mass spectrometry
- adverse drug
- contrast enhanced